Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

• Published in: Nature biotechnology 2007-01, Vol.25 (1), p.84-90
• Main Authors: Marks, Paul A, Breslow, Ronald
• Format: Article
• Language: English
• Subjects: Agriculture; Animals; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Bioinformatics; Biological and medical sciences; Biomedical and Life Sciences; Biomedical Engineering/Biotechnology; Biomedicine; Biotechnology; Cell Proliferation - drug effects; Chemotherapy; Clinical Trials as Topic; Dimethyl Sulfoxide - administration & dosage; Drug Design; Enzymes; Fundamental and applied biological sciences. Psychology; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids - administration & dosage; Inhibitor drugs; Life Sciences; Lymphoma; Medical sciences; Mortality; Neoplasm Proteins - metabolism; Neoplasms - drug therapy; Neoplasms - metabolism; Oncology; perspective; Pharmacology; Pharmacology. Drug treatments; Treatment Outcome; Tumors
• ISSN: 1087-0156; 1546-1696
• DOI: 10.1038/nbt1272

In our quest to understand why dimethyl sulfoxide (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor. SAHA reacts with and blocks the catalytic site of these enzymes. Extensive structure-activity studies were done along the path from DMSO to SAHA. SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concentrations not toxic to normal cells. SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-associated histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death. In clinical trials, SAHA has shown significant anticancer activity against both hematologic and solid tumors at doses well tolerated by patients. A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma. More potent analogs of SAHA have shown unacceptable toxicity.